Study 1
Design
An early clinical observation evaluated aqueous and defatted ethanolic extracts of Bacopa monnieri in 24 adults presenting with varied neurological and neurobehavioral challenges. Participants received either 64 mL of an aqueous extract (equivalent to 50 g fresh plant material) or 2-4 mg of a defatted ethanolic extract (1 mg equivalent to 200 mg fresh plant material) administered orally each day for five months.
Results
Participants receiving the aqueous extract showed favorable changes in neurological activity patterns in approximately half of the observed cases, while those receiving the defatted ethanolic extract showed similar changes in a greater proportion of participants. In a small number of individuals, these observations persisted throughout the study period. When used alongside standard care, the extract was generally well tolerated. Additional observations in some participants included improvements in behavioral parameters, sleep quality, mental alertness, and mood balance, while no meaningful changes were observed in certain neuropsychiatric presentations. Routine hematological and urinary biochemical parameters remained within normal ranges for all participants.
Study 2
Summary
A separate observational study involving 13 adults assessed the effects of a defatted ethanolic extract of Bacopa monnieri over a five-month period. Participants demonstrated favorable changes in neurological activity patterns over two to five months of supplementation, with several individuals showing sustained responses.
These findings are based on clinical observations and do not imply diagnosis, treatment, or prevention of any disease. Results reflect historical research data and support the potential role of Bacopa monnieri in maintaining healthy neurological function.